Download PDF
Dtsch Med Wochenschr 2010; 135(23): 1198-1200
DOI: 10.1055/s-0030-1247868
Kommentar | Commentary
Infektiologie, Immuntherapie
© Georg Thieme Verlag KG Stuttgart · New York

Pneumokokkenimpfung und Serotypen-Replacement: Brauchen wir ein neues Impf(stoff)konzept?

Pneumococcal vaccination and serotype replacement: Do we need new vaccination concepts? S. Kenzel1 , 2 , M. Hufnagel1 , R. Berner1 , P. Henneke1 , 2
  • 1Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Freiburg
  • 2Centrum für Chronische Immundefizienz, Universitätsklinikum Freiburg
Further Information

Publication History

eingereicht: 19.1.2010

akzeptiert: 18.3.2010

Publication Date:
17 May 2010 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

invasive Pneumokokkeninfektion - Pneumokokken-Serotypen - Impfung - Polysaccharid-Impfstoffe - Konjugatvakzine - Serotypen-Replacement

Keywords

invasive pneumococcal disease - pneumococcal serotypes - vaccination - polysaccharide vaccine - conjugate vaccine - serotype replacement

Literatur

  • 1 Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction.  Morb Mortal Wkly Rep. 2008;  57 144-148
    Google Scholar
  • 2 Bae S, Lee K. Distribution of capsular serotypes and macrolide resistance mechanisms among macrolide-resistant Streptococcus pneumoniae isolates in Korea.  Diagn Microbiol Infect Dis. 2009;  63 213-216
    Google Scholar
  • 3 Barocchi M A, Censini S, Rappuoli R. Vaccines in the era of genomics: the pneumococcal challenge.  Vaccine. 2007;  25 2963-2673
    Google Scholar
  • 4 Black S, Lieu T A, Ray G T, Capra A, Shinefield H R. Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente.  Vaccine,. 2000;  19 Suppl 1, S83-86
    Google Scholar
  • 5 Black S, Shinefield H. et al . Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children.  Pediatr Infect Dis J. 2000;  19 187-195
    Google Scholar
  • 6 Choi E H, Kim S H, Eun B W. et al . Streptococcus pneumoniae serotype 19A in children, South Korea.  Emerg Infect Dis. 2008;  14 275-281
    Google Scholar
  • 7 Douglas R M, Hansman D, Miles H B, Paton J C. Pneumococcal carriage and type-specific antibody.  Am J Dis Child. 1986;  140 1183-1185
    Google Scholar
  • 8 Go C, Asnis D S, Saltzman H. Pneumococcal pericarditis since 1980.  Clin Infect Dis. 1998;  27 1338-1340
    Google Scholar
  • 9 Hamel J, Charland N, Pineau I. et al . Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins.  Infect Immun. 2004;  72 2659-2670
    Google Scholar
  • 10 Hicks L A, Harrison L H, Flannery B. et al . Incidence of pneumococcal disease due to non pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998 – 2004.  J Infect Dis. 2007;  196 1346-1354
    Google Scholar
  • 11 Huss A, Scott P, Stuck A E, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults.  CMAJ. 2009;  180 48-58
    Google Scholar
  • 12 Imohl M, Reinert R R, van der Linden M. Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states.  Int J Med Microbiol. 2009;  300 237-247
    Google Scholar
  • 13 Juhn Y J, Kita H, Yawn B P. et al . Increased risk of serious pneumococcal disease in patients with asthma.  J Allergy Clin Immunol. 2008;  122 719-723
    Google Scholar
  • 14 Klacsmann P G, Bulkley B H, Hutchins G M. The changed spectrum of purulent pericarditis.  Am J Med. 1977;  63 666-673
    Google Scholar
  • 15 Kyaw M H, Lynfield R, Schaffner W. et al . Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.  N Engl J Med. 2006;  354 1455-1463
    Google Scholar
  • 16 Levine O S, Farley M, Harrison L H. et al . Risk factors for invasive pneumococcal disease in children.  Pediatrics. 1999;  103 E28
    Google Scholar
  • 17 Malley R. Antibody and cell-mediated immunity to Streptococcus pneumoniae.  J Mol Med. 2010;  88 135-142
    Google Scholar
  • 18 Obaro S K, Adegbola R A, Banya W A, Greenwood B M. Carriage of pneumococci after pneumococcal vaccination.  Lancet. 1996;  348 271-272
    Google Scholar
  • 19 Ogunniyi A D, Grabowicz M, Briles D E, Cook J, Paton J C. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae.  Infect Immun. 2007;  75 350-357
    Google Scholar
  • 20 Pletz M W, Maus U, Hohlfeld J M, Lode H, Welte T. Pneumokokkenimpfung: Konjugatimpfstoff induziert Herdenimmunität und reduziert Antibiotikaresistenz.  Dtsch med Wochenschr. 2008;  133 358-362
    Google Scholar
  • 21 Reinert R R, Haupts S, van der Linden M. et al . Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001 – 2003.  Clin Microbiol Infect. 2005;  11 985-991
    Google Scholar
  • 22 Spratt B G, Greenwood B M. Prevention of pneumococcal disease by vaccination.  Lancet. 2000;  356 1210-1211
    Google Scholar
  • 23 Stephens D S, Zughaier S M. et al . Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine.  Lancet. 2005;  365 855-863
    Google Scholar

PD Dr. med. Philipp Henneke

Centrum für Chronische Immundefizienz, Zentrum für Kinderheilkunde und Jugendmedizin

Mathildenstr. 1

79106 Freiburg

Phone: 0761/270-7764

Fax: 0761/270-7760

Email: philipp.henneke@uniklinik-freiburg.de

      >